Cardiac Angiosarcoma International Registry

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Histological Confirmation: A confirmed diagnosis of cardiac angiosarcoma through histopathological examination, including subtypes such as hemangiosarcoma and epithelioid hemangiosarcoma.
* Diagnosis Timing: Eligible patients must have been diagnosed between January 2015 and January 2035.
* Geographical Representation: Participants should be from diverse geographical locations to ensure a comprehensive understanding of the disease across different populations.
* Treatment Status: Patients who have received any treatment (surgery, chemotherapy, immunotherapy or radiation) for cardiac angiosarcoma may be included to evaluate treatment outcomes.
* Informed Consent: For prospective patients, informed consent must be obtained before they are included in the registry.
* Clinical Data Availability: Relevant clinical data, including demographics, tumor characteristics (size, location), treatment regimens, and outcomes, must be available for analysis.
* Follow-Up Willingness: Participants should be willing to undergo follow-up assessments as part of the registry's data collection efforts.

Exclusion Criteria:

* Patients who decline to provide informed consent.
* Cases where cardiac involvement is secondary to another primary malignancy